Drug Profile
Hexyl aminolevulinate - Photocure
Alternative Names: 5-ALA hexylester; 5-ALA hexylesther; aminolevulinic acid hexyl ester; APL-1702; APL-1706; Cevira; Cysview; HAL-PDT; hexaminolevulinate; Hexvix; Hexvix PDT; hexyl 5-aminolevulinate; P 1206Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator PhotoCure
- Developer Asieris Pharmaceuticals; Genotests; Ipsen; Juno Pharmaceuticals; Photocure
- Class Amino acids; Antineoplastics; Esters; Imaging agents; Levulinic acids; Oxidants; Small molecules
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bladder cancer
- Preregistration Cervical intraepithelial neoplasia
- Discontinued Colorectal cancer
Most Recent Events
- 18 Mar 2024 Efficacy and adverse events data from a phase III trial in Cervical intraepithelial neoplasia released by Photocure
- 18 Mar 2024 Aesieris and PhotoCure announces intention to submit NDA to Chinese National Medical Products Administration (NMPA) for Cervical intraepithelial neoplasia in Q2 2024
- 29 Nov 2023 Preregistration for Bladder cancer (Diagnosis) in China (Intravesicular)